ProfileGDS4814 / ILMN_1743034
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 83% 84% 85% 83% 84% 84% 83% 83% 84% 82% 84% 83% 83% 84% 83% 84% 83% 82% 82% 82% 82% 82% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)186.97183
GSM780708Untreated after 4 days (C2_1)217.72784
GSM780709Untreated after 4 days (C3_1)221.16185
GSM780719Untreated after 4 days (C1_2)181.48683
GSM780720Untreated after 4 days (C2_2)215.52484
GSM780721Untreated after 4 days (C3_2)219.16384
GSM780710Trastuzumab treated after 4 days (T1_1)185.75883
GSM780711Trastuzumab treated after 4 days (T2_1)197.61283
GSM780712Trastuzumab treated after 4 days (T3_1)209.16784
GSM780722Trastuzumab treated after 4 days (T1_2)180.77482
GSM780723Trastuzumab treated after 4 days (T2_2)200.22584
GSM780724Trastuzumab treated after 4 days (T3_2)189.91883
GSM780713Pertuzumab treated after 4 days (P1_1)187.72583
GSM780714Pertuzumab treated after 4 days (P2_1)210.85484
GSM780715Pertuzumab treated after 4 days (P3_1)189.36683
GSM780725Pertuzumab treated after 4 days (P1_2)206.51184
GSM780726Pertuzumab treated after 4 days (P2_2)188.68883
GSM780727Pertuzumab treated after 4 days (P3_2)175.37882
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)177.282
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)169.24682
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)178.94382
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)175.12382
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)183.59583